TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Evidence that cholesterol-lowering drugs prevent or treat Alzheimer’s remains inconclusive. A Danish study found lower dementia risk among people with Type 2 diabetes who used statins, and a Phase 3 trial of obicetrapib reported a change in an Alzheimer’s blood biomarker among ApoE4 carriers; neither finding establishes that the drugs prevent or treat the disease.
Two recent lines of research have renewed questions about whether cholesterol-lowering drugs could affect Alzheimer’s: a Danish observational study linked statin use with lower dementia risk in people with Type 2 diabetes, while a Phase 3 trial of obicetrapib found a change in an Alzheimer’s-related blood biomarker in a subgroup carrying the ApoE4 risk gene. Neither result shows that lowering cholesterol prevents or treats Alzheimer’s, and researchers say the biomarker finding needs follow-up in a trial measuring disease-related outcomes.
The Danish study, published in The Lancet Regional Health – Europe, analyzed health records for more than 130,000 people with Type 2 diabetes. According to the report, those who began statins earlier had a 15% lower risk of dementia over a decade; those who started later had a 10% lower risk. Because the researchers analyzed existing records rather than randomly assigning treatment, the findings show an association, not proof that statins caused the difference.
Another limitation is that people who take statins may differ in other ways from people who do not. Mayo Clinic neurologist David Knopman told Being Patient that statin users may be more medically informed and more likely to follow health-promoting behaviors, making the groups difficult to compare. A randomized trial in healthy adults older than 70 also did not find that statins prevented dementia, the report says.
The newer drug finding concerns obicetrapib, a CETP inhibitor developed by NewAmsterdam Pharma. In a subgroup of 1,727 ApoE4 carriers in a Phase 3 trial involving people with heart disease or a genetic form of high cholesterol, the drug lowered blood levels of pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A biomarker change is not the same as evidence of improved memory, slower decline or fewer diagnoses. The company has started enrolling participants in a Phase 2b Alzheimer’s trial to study biomarker effects over a year in people with disease hallmarks but no symptoms.
Why Biomarker Changes Need Follow-Up
The findings matter because they point to different possible links between cholesterol treatment and dementia: a possible association with lower risk in long-term records, and a measurable change in a blood marker in a drug trial. But neither establishes a clinical benefit. Lower pTau-217 does not by itself show that Alzheimer’s pathology has changed in a way that improves a person’s health, and the Danish results could reflect differences between patients rather than a drug effect.
That distinction is relevant to patients and clinicians weighing medicines for cardiovascular reasons. Statins are used to lower cardiovascular risk, and guidelines cited in the report recommend them for many people with Type 2 diabetes. The Alzheimer’s findings do not justify taking a statin or obicetrapib specifically to prevent or treat dementia. Decisions about cholesterol medicines should be made with a qualified health professional based on established indications and individual circumstances.
Popular right now
Ninja Foodi 10-Qt DualZone Smart XL Air Fryer, 6-in-1, DZ550
Vitamix Propel Series 750 Professional-Grade Blender, 4 Programs, Black
Breville Bambino Espresso Machine, Brushed Stainless Steel (BES450BSS)
As an affiliate, we earn on qualifying purchases.
Why Statins and Alzheimer’s Differ
Cholesterol is transported through the body by particles including LDL and HDL. The report notes that cholesterol in the blood does not pass directly into the brain; the brain has its own cholesterol metabolism. Researchers are studying whether disruptions in that system contribute to Alzheimer’s, including in people with ApoE4, a genetic risk factor associated with both Alzheimer’s and cardiovascular disease.
Statins lower cholesterol in the blood but do not readily enter the brain, according to the report. That has led some researchers to doubt they can directly alter brain cholesterol metabolism. Clinical trials conducted more than a decade ago did not show that statins treated cognitive decline, and a later trial in healthy older adults found no dementia-prevention effect. However, those results do not settle every question about timing, populations or other drug classes. The Danish analysis offers long follow-up but cannot establish cause and effect; obicetrapib’s biomarker result is an early signal, not a treatment result.
““What that means … it’s unknown.””
— David Knopman, Mayo Clinic neurologist, speaking to Being Patient
What the Findings Cannot Show
It remains unknown whether the lower dementia risk in the Danish study was caused by statin use. Differences in participants’ health behaviors, medical care or other characteristics could help explain the association. The report does not establish that the findings apply to people without Type 2 diabetes or to people already experiencing cognitive impairment.
For obicetrapib, the reported Phase 3 result concerns a blood biomarker in a subgroup, not a demonstrated change in cognition or Alzheimer’s progression. The available source does not provide enough detail to determine whether the biomarker change predicts a meaningful benefit for patients. It also does not report the size of that change. Whether the Phase 2b study will find a sustained biomarker effect, and whether any such effect would translate into clinical benefit, remains to be seen.
The Next Test for Obicetrapib
NewAmsterdam Pharma has enrolled the first participant in its Phase 2b Alzheimer’s trial. The study is expected to examine whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The reported information does not specify when results are expected or whether the trial will measure cognitive outcomes.
Researchers would need evidence from well-designed studies showing effects on cognition, daily function or disease progression before concluding that a cholesterol-lowering drug can prevent or treat Alzheimer’s. Further work would also need to clarify who might benefit and whether findings from biomarker studies apply beyond the groups tested.
Key Questions
Has a cholesterol-lowering drug been shown to prevent Alzheimer’s?
No. The Danish statin study found an association with lower dementia risk in people with Type 2 diabetes, but it was observational and cannot show that statins caused the difference. A randomized trial in healthy adults over 70 did not find a dementia-prevention effect, according to the report.
What did the obicetrapib trial find?
In a subgroup of 1,727 ApoE4 carriers, obicetrapib lowered blood levels of pTau-217, an Alzheimer’s-related biomarker. The reported result does not show that participants had better cognition or slower disease progression.
Does a lower pTau-217 level mean Alzheimer’s has been treated?
Not on the evidence reported. A biomarker change can prompt further research, but it does not by itself establish a meaningful clinical benefit. The significance of the change remains unknown.
Should someone take a statin to reduce Alzheimer’s risk?
The findings do not support starting a statin specifically to prevent Alzheimer’s. Statins may be prescribed for cardiovascular reasons, and decisions about medication should be discussed with a qualified health professional.
Source: rss
